Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
PRIORITY PRESS - 107th Annual Meeting of the American Urological Association
Bone-targeted Therapies for Patients with Advanced Prostate Cancer
Atlanta, Georgia / May 19-24, 2012
Atlanta - Most patients with advanced prostate cancer will experience at least one skeletal-related event (SRE) without bone-directed therapy. In men with castration-resistant disease, an intravenous bisphosphonate and an anti-RANK ligand...
PRIORITY PRESS - 107th Annual Meeting of the American Urological Association
Examining New Treatment Options for Overactive Bladder Syndrome
Atlanta, Georgia / May 19-24, 2012
Atlanta - Overactive bladder (OAB) has a negative impact on health-related quality of life for millions of people. The OAB symptom complex includes urgency, frequency and nocturia, and a third of patients with OAB are incontinent. It may...
PRIORITY PRESS - 27th Annual Congress of the European Association of Urology (EAU)
Treating Lower Urinary Tract Symptoms in Men with Benign Prostatic Hypertrophy
Paris, France / February 24-28, 2012
Paris - Lower urinary tract symptoms (LUTS) associated with benign prostatic hypertrophy (BPH) are common in middle-aged or older men. Agents that inhibit α1-adrenoceptors (α-blockers) are the therapy of choice recommended by...
PRIORITY PRESS - 17th International Meeting of the European Society of Gynecological Oncology
Emerging Therapies for Advanced Ovarian Cancer
Milan, Italy / September 11-14, 2011
Chief Medical Editor: Dr. Léna Coïc, Montréal, Quebec Generally, platinum sensitivity refers to a platinum-free interval (PFI) >12 months. However, that definition does not address a substantial proportion of patients...
PRIORITY PRESS - 66th Annual Meeting of the Canadian Urological Association / First CUA Primary Care Meeting
Urological Issues in Aging Patients
Montreal, Québec / June 18-21, 2011
Chief Medical Editor: Dr. Léna Coïc, Montreal, Québec Incontinence Management Urinary incontinence may result from bladder overactivity and/or dysfunction or weakening of the urinary sphincter or pelvic floor muscles...
PRIORITY PRESS - 47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
New Directions in Castration-resistant Prostate Cancer Management
Chicago, Illinois / June 3-7, 2011
Chief Medical Editor: Dr. Léna Coïc, Montréal, Québec Data from 5 phase III studies for the treatment of castration-resistant prostate cancer (CRPC) were presented during the 2011 ASCO annual meeting. Some...
PRIORITY PRESS - 112th Annual Digestive Disease Week
Colon Cancer Prevention: From Prophylaxis in UC Patients to Adequate Bowel Preparation for Colonoscopy
Chicago, Illinois / May 7-10, 2011
Chicago - New data are providing guidance for further improving already important strategies for the prevention of colorectal cancer. As demonstrated here at DDW, in one series of studies, the effort to isolate a therapeutic mechanism which...
PRIORITY PRESS - 26th Annual Congress of the European Association of Urology
Emerging Clarity in the Identification and Treatment of Overactive Bladder in Men
Vienna, Austria / March 18-22, 2011
Vienna - Antimuscarinic agents are first-line therapy for overactive bladder (OAB) based on results of multiple controlled studies, but the challenge in men has been differentiating OAB from other forms of lower urinary tract symptoms...
PRIORITY PRESS - 26th Annual Congress of the European Association of Urology
Importance of Rapid and Profound Suppression of Hormone Levels in Prostate Cancer Now Supported by PSA Progression-free Survival
Vienna, Austria / March 18-22, 2011
Vienna - Newly released data from an ongoing extension study demonstrate outcome advantages for an antagonist relative to an agonist of gonadotropin-releasing hormone (GnRH) for prostate cancer. Specifically, patients switched to an...